MTCR · Metacrine, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2021 | FY 2020 |
|---|---|---|
| Revenue | - | - |
| Cost of Revenue | - | - |
| Gross Profit | - | - |
| R&D | $45.47M | $26.79M |
| SG&A | $15.61M | $9.90M |
| Total Operating Expenses | $61.08M | $36.69M |
| D&A | $295.0K | $307.0K |
| Operating Income | ($61.08M) | ($36.69M) |
| Interest Expense | $1.20M | $1.01M |
| Income Tax | $0 | $0 |
| Net Income | ($62.21M) | ($37.30M) |
| EPS - Basic | - | - |
| EPS - Diluted | - | - |
Balance Sheet
| Line item | FY 2021 | FY 2020 |
|---|---|---|
| Cash & Equivalents | $48.91M | $24.39M |
| Accounts Receivable | - | - |
| Inventory | - | - |
| Accounts Payable | $368.0K | $334.0K |
| Current Assets | $78.74M | $102.02M |
| Total Assets | $79.99M | $104.24M |
| Current Liabilities | $7.76M | $4.03M |
| Long-term Debt | $13.30M | $9.37M |
| Total Liabilities | - | - |
| Stockholders' Equity | $57.35M | $89.28M |
| Retained Earnings | ($182.95M) | ($120.75M) |
Cash Flow
| Line item | FY 2021 | FY 2020 |
|---|---|---|
| Operating Cash Flow | ($47.16M) | ($36.21M) |
| Investing Cash Flow | $43.91M | ($32.10M) |
| Financing Cash Flow | $27.77M | $77.03M |
| CapEx | $8.0K | $206.0K |
| Free Cash Flow | ($47.17M) | ($36.42M) |
Ratios
| Metric | FY 2021 | FY 2020 |
|---|---|---|
| Profitability | ||
| Gross margin | - | - |
| Operating margin | - | - |
| EBITDA margin | - | - |
| Net margin | - | - |
| Free cash flow margin | - | - |
| FCF / Net income | 0.76 | 0.98 |
| R&D / Revenue | - | - |
| SG&A / Revenue | - | - |
| Effective tax rate | - | - |
| Return on assets | -77.8% | -35.8% |
| Return on equity | -108.5% | -41.8% |
| Return on invested capital | -68.3% | -29.4% |
| Liquidity | ||
| Current ratio | 10.15 | 25.34 |
| Quick ratio | 10.15 | 25.34 |
| Cash ratio | 6.30 | 6.06 |
| Leverage | ||
| Debt / Equity | 0.23 | 0.10 |
| Debt / Assets | 0.17 | 0.09 |
| Debt / EBITDA | - | - |
| Interest coverage | -50.8x | -36.3x |
| Equity multiplier | 1.39 | 1.17 |
| Liabilities / Assets | - | - |
| Efficiency | ||
| Asset turnover | - | - |
| Inventory turnover | - | - |
| Days sales outstanding | - | - |
| Days inventory outstanding | - | - |
| Days payable outstanding | - | - |
| Cash conversion cycle | - | - |
| Valuation | ||
| P / E | - | - |
| P / B | - | - |
| P / S | - | - |
| EV / EBITDA | - | - |
| Growth | ||
| Revenue growth (YoY) | - | - |
| Revenue CAGR (3y) | - | - |
| Revenue CAGR (5y) | - | - |
| Gross profit growth (YoY) | - | - |
| Operating income growth (YoY) | -66.5% | - |
| Net income growth (YoY) | -66.8% | - |
| EPS growth (YoY) | - | - |
| EPS CAGR (3y) | - | - |
| EPS CAGR (5y) | - | - |
| FCF growth (YoY) | -29.5% | - |
| FCF CAGR (5y) | - | - |
| Book value growth (YoY) | -35.8% | - |
Stability scores
Piotroski F-score
FY 2021 · 9-point quality
1/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- ✗Long-term debt decreased
- ✗Current ratio improved
- -No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Metacrine against the 5 most active filers in the same SIC group.